BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang L, Yan B, Liu Y, Jiang S, He H, Huang J, Liu W, Xie L, Zhang Y. FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature. Disease Markers 2022;2022:1-21. [DOI: 10.1155/2022/4534080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Peng J, Yang S, Ng CSH, Chen GG. The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials. Pharmacol Ther 2023;241:108333. [PMID: 36528259 DOI: 10.1016/j.pharmthera.2022.108333] [Reference Citation Analysis]
2 Zhang B, Xie L, Liu J, Liu A, He M. Construction and validation of a cuproptosis-related prognostic model for glioblastoma. Front Immunol 2023;14:1082974. [PMID: 36814929 DOI: 10.3389/fimmu.2023.1082974] [Reference Citation Analysis]
3 He H, Liang L, Huang J, Jiang S, Liu Y, Sun X, Li Y, Cong L, Jiang Y. KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma. Front Pharmacol 2022;13:1007429. [DOI: 10.3389/fphar.2022.1007429] [Reference Citation Analysis]
4 Liang L, He H, Jiang S, Liu Y, Huang J, Sun X, Li Y, Jiang Y, Cong L. TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma. IJMS 2022;23:10415. [DOI: 10.3390/ijms231810415] [Reference Citation Analysis]